Results 251 to 260 of about 1,132,887 (301)
Some of the next articles are maybe not open access.
Antiepileptic drugs in neuroprotection
Expert Opinion on Pharmacotherapy, 2004Antiepileptic drugs (AEDs) are designed to prevent and suppress seizure activity. Their effects on calcium influx and molecular cascades contributing to necrotic and apoptotic neuronal death, however, suggests that they have functions other than just suppression of excitability.
Asla, Pitkänen, Hana, Kubova
openaire +2 more sources
Current Neurology and Neuroscience Reports, 2001
Eight novel anticonvulsant drugs have been introduced in the United States in the past 10 years, as well as two new intravenous preparations of anticonvulsant drugs. The role of each in the treatment of patients with epilepsy is being refined as experience and research data accumulate.Gabapentin, tiagabine, and oxcarbazepine are effective for partial ...
openaire +3 more sources
Eight novel anticonvulsant drugs have been introduced in the United States in the past 10 years, as well as two new intravenous preparations of anticonvulsant drugs. The role of each in the treatment of patients with epilepsy is being refined as experience and research data accumulate.Gabapentin, tiagabine, and oxcarbazepine are effective for partial ...
openaire +3 more sources
Withdrawal of antiepileptic drugs
Current Opinion in Neurology, 1995Recent literature on withdrawing antiepileptic drug therapy in patients who are seizure free on antiepileptic drugs is reviewed. The average recurrence risk across studies is 29% at 2 years. Factors such as age of onset, etiology of seizures, the electroencephalogram and the epileptic syndrome influence outcome.
S, Shinnar, A T, Berg
openaire +2 more sources
Current Opinion in Neurology, 1996
The physician's choice of antiepileptic drug for a particular patient should be based on firm evidence. The current body of evidence generated from randomized, controlled monotherapy trials is discussed. Attention is focused on four recently published randomized trials in which monotherapy with one drug is compared with monotherapy with another.
A G, Marson, D, Chadwick
openaire +2 more sources
The physician's choice of antiepileptic drug for a particular patient should be based on firm evidence. The current body of evidence generated from randomized, controlled monotherapy trials is discussed. Attention is focused on four recently published randomized trials in which monotherapy with one drug is compared with monotherapy with another.
A G, Marson, D, Chadwick
openaire +2 more sources
Analysis of antiepileptic drugs
Journal of Chromatography B: Biomedical Sciences and Applications, 1990This review discussed various analytical methods for the determination of antiepileptic drugs and their metabolites in biological tissues. The emphasis was on the reports published since their last review [J. T. Burke and J. P. Thenot, J. Chromatogr., 340 (1985) 199]. Both chromatographic and immunological procedure were cited and compared. Methods for
openaire +2 more sources
Antiepileptic drugs and puberty
Brain and Development, 1988This paper investigates pubertal development in 57 epileptic subjects, ranging in age from 6 to 15 years, under anti-epileptic therapy for at least 2 years. The results were compared with those from a control group of healthy volunteers. The onset of stage II puberty was significantly earlier in both male and female treated epileptics than in healthy ...
A, Nalin +5 more
openaire +2 more sources
Neurology, 1994
Abstract After 1977, no new antiepileptic drugs (AEDs) were available until felbamate was approved in 1993. Since then, three more new AEDs have been approved for use in the United States: gabapentin, lamotrigine, and topiramate. These new medications have greatly improved the medical treatment of epilepsy.
openaire +2 more sources
Abstract After 1977, no new antiepileptic drugs (AEDs) were available until felbamate was approved in 1993. Since then, three more new AEDs have been approved for use in the United States: gabapentin, lamotrigine, and topiramate. These new medications have greatly improved the medical treatment of epilepsy.
openaire +2 more sources
Pediatric Annals, 2015
Epilepsy is a common neurological condition that affects approximately 1% of the general population. In addition, about 10% of the population experiences a seizure sometime during life. The treatment options for epilepsy have come a long way from the bromides to the current era in which we now have multiple treatment modalities, including ...
Ram, Sankaraneni, Deepak, Lachhwani
openaire +2 more sources
Epilepsy is a common neurological condition that affects approximately 1% of the general population. In addition, about 10% of the population experiences a seizure sometime during life. The treatment options for epilepsy have come a long way from the bromides to the current era in which we now have multiple treatment modalities, including ...
Ram, Sankaraneni, Deepak, Lachhwani
openaire +2 more sources
EVALUATION OF ANTIEPILEPTIC DRUGS
Archives of Neurology And Psychiatry, 1950TWO PRINCIPAL electric shock methods have been employed for the laboratory appraisal of anticonvulsant drugs: ( a ) the method of Putnam and Merritt 1 and ( b ) that of Toman, Swinyard and Goodman. 2 In the former, the anticonvulsant potency of a compound is determined by its ability to raise the electric shock convulsion threshold in the cat ...
G, CHEN, C R, ENSOR
openaire +2 more sources
Annals of Clinical Biochemistry: International Journal of Laboratory Medicine, 1999
Approximately 20 to 30% of patients with newly diagnosed epilepsy do not have their seizures controlled with currently available antiepileptic drugs. The clinical need for new antiepileptic drugs is therefore clear.
openaire +2 more sources
Approximately 20 to 30% of patients with newly diagnosed epilepsy do not have their seizures controlled with currently available antiepileptic drugs. The clinical need for new antiepileptic drugs is therefore clear.
openaire +2 more sources